Drug companies rejected the coronary vaccine in 2017

The plan to speed up development and approval of vaccines was presented by European Commission representatives, but was rejected by industry partners in the body. The Commission's argument was that early production of vaccines “could prevent a real outbreak of the virus. The pharmaceutical companies, however, rejected the idea.

The news is made known by the British newspaper “The Guardian”, which has published a report published by the European Corporations (COE), a Brussels-based research centre that collects EU organisations and some of the biggest pharmaceutical names, among them GlaxosSmithKline, Novatitis, Pfizer, Lilly and Johnson & Johnson.

Coronervirus' uncertainty has already led to strong accusations in recent weeks that the pharmaceutical industry has failed to establish priorities for infectious diseases because they are less profitable than chronic diseases.

20 largest pharmaceutical companies in the world undertaken about 400 new research projects in the past year, and half were focused on cancer treatment and only 65 were for infectious diseases.

There are eight possible vaccines for the coronary still in clinical trials, but there is no guarantee of success. One vaccine, under way at Oxford University, is said to have only 50% access to use.

“The Guardian” says that instead of focusing now on infectious diseases, pharmaceutical companies are continuing to focus on market priorities as usual”

In response to the report, a spokeswoman for COE said infectious diseases and vaccines had been the priority since. It highlighted a 20m-euro project undertaken in 2015 after Ebola. Journal Si